INTRACELLULAR CALCIUM

CALMODULIN

PROTEINS

SE-101
Calmodulin (from bovine brain)
>99% by SDS-PAGE, MW=16.7 kDa, [73298-54-1] Storage: -20°C
Supplied lyophilized. Specific activity: 13,000 units/mg protein. One unit will activate 3',5'-cyclic nucleotide phosphodiesterase to 50% V_max. Can be used to activate CaM-dependent phosphodiesterase, calcineurin, CaM kinases, etc.
1 mg
5 x 1 mg

SE-102
Calmodulin, immobilized (from bovine brain)
Storage: 4°C
Conjugated to 4% cross-linked agarose beads via a 5 atom hydrophilic spacer arm. Calmodulin concentration is 1 mg/ml beads, supplied as a suspension.
1 ml

CALMODULIN INHIBITORS

CA-300
Calmidazolium chloride (R24571)
99%, MW=687.7 [57265-65-3] Storage: -20°C
Binds reversibly to calmodulin, inhibiting calmodulin mediated enzyme activation¹. It inhibits the Ca²⁺/calmodulin-induced activation of myosin light chain kinase in a concentration dependent manner (IC₅₀=1 µM)². Cell permeable³. Inhibits calmodulin N-methyltransferase (K_i=65 nM)⁴.
10 mg
50 mg

P-200
CaM kinase II (290-309), calmodulin antagonist
Leu-Lys-Lys-Phe-Asn-Ala-Arg-Arg-Lys-Leu-Lys-Gly-Ala-Ile-Leu-Thr-Thr-Met-Leu-Ala
>97%, MW=2274.1 [115044-69-4] Storage: -20°C
Synthetic peptide with sequence from Ca²⁺/calmodulin-dependent protein kinase II pseudosubstrate site. Peptide binds calmodulin tightly and inhibits calmodulin-requiring enzymes including CaMKII, phosphodiesterase and calcineurin. IC₅₀=52 nM for CaMKII in the presense of 100 nM calmodulin⁵.
0.5 mg
5 x 0.5 mg

CA-302
E₆ Berbamine
98%, MW=757.8, Storage: -20°C
A new, potent, selective, cell permeable calmodulin antagonist. It inhibits calmodulin dependent enzymes such as MLC kinase (IC₅₀=8 µM) and phosphodiesterase I (IC₅₀=0.53 µM)⁶.
10 mg
50 mg

CA-325
Fluphenazine-N-2-chloroethane?HCl (SKF-7171A; Fluphenazine-N-mustard)
98%, MW=528.6 [83016-35-7] Storage: RT
A potent irreversible inactivator of calmodulin⁷. Possesses potent antiproliferative and cytotoxic activity7. It is also an irreversible D₂ dopamine receptor antagonist⁸.
50 mg
250 mg

CA-305
Phenoxybenzamine·HCl
99%, MW=340.3 [63-92-3] Storage: RT
Irreversibly inhibits calmodulin⁹. Cell permeable. Selective a-adrenergic blocker.
200 mg
1 g

CA-310
Trifluoperazine?HCl (stelazine)
98%, MW=480.4 [440-17-5] Storage: RT
Facilitates agonist induced elevation of cytosolic calcium at low concentrations (10 µM). Antagonizes calmodulin at higher concentrations¹⁰. Cell permeable.
1 g
5 g

CA-315
W-5
N-(6-Aminohexyl)-1-naphthalenesulfonamide·HCl
98%, MW=342.9 [61714-25-8] Storage: RT
Binds to calmodulin, inhibiting Ca²⁺-calmodulin regulated enzyme activity^11,12. Cell permeable.
20 mg
100 mg

CA-320
W-7
N-(6-Aminohexyl)-5-chloro-1-naphthalenesulfonamide·HCl
99%, MW=377.4 [61714-27-0] Storage: RT
Binds to calmodulin, inhibiting Ca²⁺-calmodulin regulated enzyme activity^11,12. It inhibits the Ca²⁺/calmodulin-induced activation of myosin light chain kinase in a concentration dependent manner (IC₅₀=25 µM)2. Cell permeable.
50 mg
250 mg

CALMODULIN ANTIBODIES

SA-118
Anti-Calmodulin
Mouse monoclonal antibody. Clone 6D4. Immunogen: Purified D. discoideum calmodulin conjugated to KLH^13,14. Supplied as IgG1 in ascites. Target is 17 kDa calmodulin from a variety of species. No reaction with parvalbumin, troponin, S-100, or MLCK. Applications: WB 1/2000 with modest inhibition in the presence of EGTA, IC, ELISA.
200 µl

SA-211
Anti-Calmodulin
Sheep polyclonal antibody. Immunogen: Highly purified bovine testes calmodulin. Supplied as serum. Recognizes human, rat, bovine and other mammalian 17 kDa calmodulin. Applications: ELISA detects 50 ng at 1:50,000 dilution.
1 ml

SERCA (SARCOPLASMIC/ENDOPLASMIC RETICULUM CALCIUM ATPase)

SERCA REAGENTS

CA-415
Cyclopiazonic acid
98%, MW=336.4 [18172-33-3] Storage: 0°C
Cyclopiazonic acid induces the release of intracellular stored Ca²⁺, without increasing IP₃ levels, via inhibition of endoplasmic reticulum Ca²⁺-ATPase¹⁵. It is a highly specific inhibitor of the Ca²⁺-ATPase of sarcoplasmic reticulum, completely inhibiting the enzyme at 6-8 nmol/mg protein (at 0.5-2 µM ATP)^16,17.
10 mg
50 mg

CA-420
2,5-Di-tert-butylhydroquinone (DBHQ)
99%, MW=222.3 [88-58-4] Storage: RT
DBHQ induces the release of Ca²⁺ from agonist-sensitive and agonist-insensitive intracellular stores without increasing IP₃ levels^15,18,19,20. Its mode of action is via inhibition of endoplasmic reticulum Ca²⁺-ATPase. It induced a rapid increase in cytosolic Ca²⁺ concentration in isolated rat hepatocytes (EC₅₀=1-2 µM)¹⁹.
1 g
5 g

CA-422
Gingerol
98%, MW=294.4 [23513-14-6] Storage: -20°C
Gingerol, an active principal of ginger rhizomes (Zingiber officinale) is a novel and selective activator of skeletal and cardiac SR Ca²⁺-ATPase (EC₅₀=4 µM)²¹. It is a novel cardiotonic agent²¹ with antiplatelet activity²².
5 mg
20 mg

PE-180
Thapsigargin
99%, MW=652.8 [67526-95-8] Storage: -20°C
Thapsigargin is a cell permeable sesquiterpene lactone tumor promotor²³. It induces the release of intracellular stored Ca²⁺ without hydrolysis of inositolphospholipids via inhibition of endoplasmic reticulum Ca²⁺-ATPase (IC₅₀=30 nM)^24,25 . It may be used to distinguish between discrete intracellular Ca²⁺ pools^26,27. Thapsigargin-induced tumor promotion²⁸ and down regulation of the EGF receptor is independent of protein kinase C activation^29,30.
1 mg
5 mg

SERCA ANTIBODIES

SA-186
Anti-SERCA1 ATPase
Mouse monoclonal antibody. Clone IIH11. Immunogen: Purified rabbit skeletal muscle sarcoplasmic reticulum^31,32. Supplied as IgG1 in diluted ascites. Recognizes sarcoplasmic and endoplasmic reticulum (SER) Ca²⁺-ATPase ~p110 kDa in rat, mouse, rabbit and dog. Epitope is between residues 199-505 of rabbit skeletal muscle Ca²⁺- ATPase, a region not exposed in native SER. Applications: WB 1/2500, IF 1/500.
100 µl

SA-187
Anti-SERCA1 ATPase
Mouse monoclonal antibody. Clone VE12₁G9. Immunogen: Purified rabbit skeletal muscle sarcoplasmic reticulum³³. Supplied as IgG1 in ascites. Recognizes sarcoplasmic and endoplasmic reticulum (SER) Ca²⁺-ATPase ~p110 kDa in human, rabbit and dog. Epitope is between residues 506 and C-terminal of rabbit skeletal muscle Ca²⁺-ATPase, a region that is exposed in native SER. Applications: WB 1/2500, IF 1/500.
100 µl

SA-185
Anti-SERCA2 ATPase
Mouse monoclonal antibody. Clone IID8. Immunogen: Purified canine cardiac sarcoplasmic reticulum³¹. Supplied as IgG1 in ascites. Recognizes SERCA2a and 2b isotypes of sarcoplasmic and endoplasmic reticulum (SER) Ca²⁺-ATPase ~p110 kDa in human, rabbit and dog³⁴. Applications: WB 1/2500, IF 1/500, IH. Does not work for WB in rat.
100 µl

SA-209
Anti-SERCA2a ATPase
Mouse monoclonal antibody. Clone 2A7-A1. Immunogen: Purified canine cardiac sarcoplasmic reticulum. Supplied as IgG2a in ascites. Recognizes SERCA2a isotype of sarcoplasmic and endoplasmic reticulum (SER) Ca²⁺-ATPase ~p110 kDa in type I (slow) skeletal, cardiac and smooth muscle in human, dog, rat and rabbit^35,36,37. Applications: WB 1/1000.
100 µl

SA-142
Anti-SERCA3 ATPase
Mouse monoclonal antibody. Clone PL/IM 430. Immunogen: Purified intracellular membrane from human platelets. Supplied as purified IgG1. Recognizes ~100 kDa SERCA3 protein found in platelets and various human cell lines^39,40,41. Does not crossreact with PMCA. Inhibits translocation of Ca²⁺ into isolated intracellular human platelet membrane vesicles (~80% at 20-30 µg/ml IgG) and in saponin-treated intact cells⁴². Does not inhibit Ca²⁺/ Mg²⁺-ATPase. Applications: WB 1-5 µg/ml, ELISA.
200 µg

RYANODINE RECEPTOR

RYANODINE RECEPTOR REAGENTS

CA-416
cADP-Ribose (cADPR)
Cyclic adenosine diphosphate-ribose
>95%, MW=541.3 [119340-53-3] Storage: -20°C
The most potent Ca²⁺ mobilizing second messenger known. It has been shown to mobilize intracellular Ca²⁺ stores in invertebrate as well as mammallian cells at low nanomolar concentrations. cADPR may function as an endogenous modulator of Ca²⁺-induced Ca²⁺ release^43,44.
100 µg
500 µg

CA-417
8-Bromo-cADP-Ribose (8-Br-cADPR)
95%, MW=620.2 [151898-26-9] Storage: -20°C
cADPR antagonist. Blocks the cADPR-induced release of Ca²⁺ from sea urchin egg homogenates at 1-3.5 µM⁴⁵.
100 µg
500 µg

CA-450
Ryanodine, high purity
>96%, MW=493.5 [15662-33-6] Storage: RT
Ryanodine is an alkaloid extracted from Ryania speciosa which displays a strong paralyzing effect in cardiac and skeletal muscle⁴⁶. It induces the release of intracellular stored Ca^{2+ 47}. Ryanodine receptors mediate adenine nucleotide, Ca²⁺, and caffeine-sensitive release of Ca²⁺ from sarcoplasmic reticulum of cardiac and skeletal muscle^48,49,50 and may also mediate intracellular Ca²⁺ release in neurons^51,52. Ryanodine has extremely slow association/dissociation kinetics⁵³ and may induce or block Ca²⁺ release depending on the concentration used⁵⁴.
5 mg
5 x 5 mg

CA-220
Ryanodine
A mixture of the alkaloids ryanodine and 9,21-dehydro-ryanodine (~1:1).
MW=493.5 [15662-33-6] Storage: RT
20 mg
100 mg

EI-110
TMB-8·HCl
8-(Diethylamino)octyl-3,4,5-trimethoxybenzoate·HCl
98%, MW=432.0 [53464-72-5] Storage: RT
Inhibits intracellular Ca²⁺ mobilization^55,56. May affect membrane conductance for Ca²⁺ and other cations^57,58.
50 mg
250 mg

RYANODINE RECEPTOR ANTIBODIES

SA-245
Anti-Ryanodine Receptor-1,2 (RyR)
Mouse monoclonal antibody. Clone 34C. Immunogen: Partially purified chicken pectoral muscle ryanodine receptor⁵⁹. Supplied as ascites IgG1. Recognizes 565 kDa RyR-1 and RyR-2 isoforms in human, bovine, sheep, canine, rat and mouse; chicken RyRa, b and cardiac isoforms; and frog RyRa and RyRb isoforms. Applications: WB 1/5000, IH 1/1000, IP.
100 µl

SA-244
Anti-Ryanodine Receptor (RyR)
Mouse monoclonal antibody. Clone C3-33. Immunogen: Canine cardiac ryanodine receptor⁶⁰. Supplied as IgG1 in diluted ascites. Recognizes 565 kDa RyR-2 and weakly with RyR-1 isotypes in dog and rat. Applications: WB 1 µg/ml, IH 1 µg/ml, IP.
100 µg

IONOPHORES AND OTHER REAGENTS

CA-100
Antibiotic A-23187(Calcimycin)
99%, MW=523.6 [52665-69-7] Storage: -20°C
A highly selective calcium ionophore¹. Useful tool for increasing intracellular Ca²⁺ concentration.
10 mg
5 x 10 mg

CA-101
Antibiotic A-23187, 4-bromo
98%, MW=602.5 [76455-82-8] Storage: -20°C
A highly selective calcium ionophore which is a useful tool for increasing intracellular Ca²⁺ concentration. A nonfluorescent analog of A-23187 and therefore useful in the presence of fluorescent probes⁶¹.
1 mg
5 x 1 mg

CA-411
BAPTA-AM
1,2-bis-(o-Aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid, tetraacetoxymethyl ester
>90%, MW=764.7 [139890-68-9] Storage: -20°C
BAPTA is a Ca²⁺ chelator^62,63 with 10⁵-fold greater affinity for Ca²⁺ than for Mg²⁺. BAPTA-AM is a cell permeable derivative which is widely used as an intracellular calcium sponge^64,65.
25 mg
5 x 25 mg

CA-412
BAPTA, free acid
1,2-bis-(o-Aminophenoxy)-ethane-N,N, N',N' -tetraacetic acid
97%, MW=476.4 [85233-19-8] Storage: -20°C
BAPTA is a Ca²⁺ chelator with 10⁵-fold greater affinity for Ca²⁺ than for Mg^2+62,63. BAPTA, free acid is not cell permeable and therefore is useful as an extracellular calcium sponge^66,67,68.
100 mg
500 mg

CA-201
Ionomycin
99%, MW=709.0 [56092-81-0] Storage: -20°C
A highly selective calcium ionophore. Useful tool for increasing intracellular Ca²⁺ concentration^69,70. More effective than A-23187 and nonfluorescent.
1 mg
5 x 1 mg

CA-421
Nigericin, sodium salt
98%, MW=747 [28380-24-7] Storage: 0°C
K⁺ and H⁺ ionophore. Stimulates Ca²⁺ release from mitochondrial stores by disruption of membrane potential⁷¹.
5 mg
5 x 5 mg

CALCITONIN

P-420
Calcitonin, Salmon (synthetic)
98%, MW=3431.9 [47931-85-1] Storage: -20°C
Calcitonin is a calcium-regulating peptide hormone released from the thyroid. It lowers calcium concentration in the blood, and decreases bone resorption by osteoclasts. It is used for therapeutic applications in osteoporosis⁷². Salmon calcitonin peptide sequence differs from mammalian but is more potent.
1 mg
5 mg

REFERENCES

1. K. Gietzen et al. Biochem. J. 1982 207 541

2. M. Asano J. Pharmacol. Exp. Ther. 1989 251 764

3. A. Schaefer et al. J. Biol. Chem. 1996 271 13484

4. L.S. Wright et al. J. Biol. Chem. 1996 271 12737

5. M.E. Payne et al. J. Biol. Chem. 1988 263 7190

6. Z.-Y. Hu et al. Biochem. Pharmacol. 1992 44 1543

7. W.N. Hait et al. Mol. Pharmacol. 1987 32 404

8. Z.H. Qiw et al. Mol. Pharmacol. 1995 48 730

9. C.Q. Earl et al. Life Sci. 1984 35 524

10. G.H.R. Rao Biochem. Biophys. Res. Commun. 1987 148 768

11. T. Tanaka et al. Pharmacology 1983 26 249

12. H. Hidaka et al. Proc. Natl. Acad. Sci. USA 1981 78 4354

13. D. Hulen et al. Cell Motil. Cytoskel. 1991 18 113

14. Q. Zhu and M.J. Clarke J. Cell Biol. 1993 121 1311

15. N. Demaurex et al. J. Biol. Chem. 1992 267 2318

16. D.E. Goeger et al. Biochem. Pharmacol. 1988 37 978

17. N.W. Seidler et al. J. Biol. Chem. 1989 264 17816

18. G.A. Moore et al. FEBS Lett. 1987 224 331

19. G.E.N. Kass et al. J. Biol. Chem. 1989 264 15192

20. S. Muallem et al. Biochem. J. 1991 279 367

21. M. Kobayashi et al. Biochim. Biophys. Acta 1987 903 96

22. J.H. Guh et al. J. Pharm. Pharmacol. 1995 47 329

23. H. Fujiki et al. Carcinogenesis 1986 7 707

24. H. Takemura et al. J. Biol. Chem. 1989 264 12266

25. O. Thastrup et al. Proc. Natl. Acad. Sci. USA 1990 87 2466

26. B. Papp et al. J. Biol. Chem. 1991 266 14593

27. J. Bian et al. J. Biol. Chem. 1991 266 8801

28. T.R. Jackson et al. Biochem. J. 1988 253 81

29. K. Takishima et al. Biochem. Biophys. Res. Commun. 1988 157 740

30. B. Friedman et al. Proc. Natl. Acad. Sci. USA 1989 86 812

31. A.O. Jorgenson et al. Cell Motil. Cytoskel. 1988 9 164

32. E. Molnar et al. Biochem. Biophys. Acta 1990 1023 147

33. C.M. Knudson et al. J. Biol. Chem. 1988 264 1345

34. A.H. Sharp et al. J. Neurosci. 1993 13 3051

35. M.A. Movsesian et al. Circulation 1994 90 653

36. H.A. Rockman et al. Proc. Natl. Acad. Sci. USA 1994 91 2694

37. L.R. Jones et al. J. Biol. Chem. 1995 270 30787

38. N. Hack et al. Biosc. Rep. 1988 8 379

39. B. Papp et al. Biochem. J. 1992 288 297

40. T. Kovacs et al. J. Biol. Chem. 1994 269 6177

41. S. Bokkala et al. Biochem. J. 1995 306 837

42. N. Hack et al. Biochem. J. 1988 250 355

43. A. Galione and A. White Trends. Cell Biol. 1994 4 431

44. H.C. Lee Cell. Signalling 1994 6 591

45. T.F. Walseth and H.C. Lee Biochim. Biophys. Acta 1993 1178 235

46. M. Reiter Pharmacologi cal Rev. 1988 40 189

47. D.W. Hilgemann Biophys. J. 1987 51 550a

48. P.S. McPherson and K.P. Campbell J. Biol. Chem. 1993 268 13765

49. N. Ikemoto et al. J. Biol. Chem. 1985 260 14096

50. G. Calviello and M. Chiesi Biochemistry 1989 28 1301

51. P.T. Toth et al. Cell Calcium 1990 11 557

52. P.S. McPherson et al. Neuron 1991 7 17

53. I.N. Pessah et al. J. Biol. Chem. 1986 261 8643

54. G. Meissner J. Biol. Chem. 1986 261 6300

55. C.Y. Chiou et al. Br. J. Pharmacol. 1985 553 279

56. M. Donowitz et al. Am. J. Physiol. 1986 250 G691

57. H.M. Himmel and U. Ravens J. Pharmacol. Exp. Ther. 1990 255 293

58. H.M. Himmel and U. Ravens J. Pharmacol. Exp. Ther. 1990 255 300

59. J.A. Airey et al. J. Biol. Chem. 1990 265 14187

60. F.A. Lai et al. Am. J. Physiol. 1992 263 C365

61. C.M. Deber and L.C. Hsu Biochem. Biophys. Res. Commun. 1986 134 731

62. S.M. Harrison et al. Biochim. Biophys. Acta 1987 925 133

63. R.Y. Tsien et al. Biochim. Biophys. Acta 1982 298 478

64. J.B. Smith et al. Biochem. J. 1992 288 925

65. A. Yoshida et al. Biochem. Biophys. Res. Commun. 1993 196 927

66. S.Y. Wu and N.J. Dun J. Neurophysiol. 1995 74 2600

67. A. Venant et al. Biol. Cell 1995 85 197

68. T. Tucker and R. Fettiplace Neuron 1995 15 1323

69. A. Dupuy d'Angeac et al. J. Cell. Physiol. 1993 154 44

70. H.C. Lee et al. J. Biol. Chem. 1993 268 293

71. A.E. Vercesi et al. J. Biol. Chem. 1993 268 8564

72. J.C. Stevenson et al. Drugs 1981 21 257